Literature DB >> 7990967

Effects of metal cations on [3H]alpha,beta-methylene ATP binding in rat vas deferens.

A D Michel1, P P Humphrey.   

Abstract

In this study we have examined the effect of metal cations (as their chloride salts) on the binding of [3H]alpha,beta-methylene ATP ([3H]alpha beta meATP) to rat vas deferens membranes using a vacuum filtration receptor binding assay. Whereas NaCl and KCl (0.01 and 30 mM) did not affect total binding of 1 nM [3H]alpha beta meATP, several divalent and trivalent cation salts markedly increased binding. The trivalent cation salts, FeCl3 and AlCl3 (0.1 to 100 microM), produced the greatest increases in total binding of [3H]alpha beta meATP, however, their effects were most probably due to precipitation of the radioligand. In contrast, several divalent cations, at concentrations between 1 microM and 1-10 mM, increased total binding of [3H]alpha beta meATP to rat vas deferens by between 87% and 215% while having no effect on either filter binding or non specific binding. The following pEC50 values for potentiating binding of the radioligand were obtained: ZnCl2 (5.44), MnCl2 (4.52), CaCl2 (4.17), CoCl2 (4.06), MgCl2 (3.67) and BaCl2 (3.10). Both EDTA and EGTA (0.01-1 mM) inhibited the binding of the radioligand. The effects of ZnCl2, CaCl2 and MgCl2 were examined in saturation studies. In the absence of added divalent cations, [3H]alpha beta meATP labelled both high (pKd = 9.15) and low (pKd = 7.06) affinity binding sites. The affinity of the radioligand for its high affinity sites was increased by 3 mM CaCl2 (pKd = 9.56) and by 30 microM ZnCl2 (pKd = 9.46) but not by 3 mM MgCl2. The Bmax of the low affinity site for [3H]alpha beta meATP was increased (approximately 4 fold) by both 3 mM MgCl2 and 30 microM ZnCl2 but not by 3 mM CaCl2. The selective effect of CaCl2 on the high affinity binding sites enabled these sites to be labelled in the presence of 3 mM CaCl2 using a low concentration of [3H]alpha beta meATP (1 nM); the sites exhibited the binding characteristics expected of the P2x purinoceptor. The selective effect of MgCl2 on the low affinity binding sites enabled these sites to be labelled in the presence of 3 mM MgCl2 and using a high concentration of [3H]alpha beta meATP (100 nM). A comparison of the binding characteristics of the high and low affinity sites for [3H]alpha beta meATP revealed several other differences, in addition to their cation selectivity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990967     DOI: 10.1007/BF00241084

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

Review 1.  Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators.

Authors:  E L Ochoa; A Chattopadhyay; M G McNamee
Journal:  Cell Mol Neurobiol       Date:  1989-06       Impact factor: 5.046

Review 2.  Biochemical properties of a P2Y-purinergic receptor.

Authors:  T K Harden; J L Boyer; H A Brown; C L Cooper; R A Jeffs; M W Martin
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  Electron spin resonance of ferromagnetic particles in airborne dust.

Authors:  L Strackee
Journal:  Nature       Date:  1968-05-04       Impact factor: 49.962

4.  Cationic channels activated by extracellular ATP in rat sensory neurons.

Authors:  O A Krishtal; S M Marchenko; A G Obukhov
Journal:  Neuroscience       Date:  1988-12       Impact factor: 3.590

5.  High- and low-affinity binding sites for [3H]-alpha, beta-methylene ATP in rat urinary bladder membranes.

Authors:  X N Bo; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

Review 6.  Signal transduction by P2-purinergic receptors for extracellular ATP.

Authors:  G R Dubyak
Journal:  Am J Respir Cell Mol Biol       Date:  1991-04       Impact factor: 6.914

7.  Triphosphate, the key structure of the ATP molecule responsible for interaction with P2X-purinoceptors.

Authors:  X Bo; G Burnstock
Journal:  Gen Pharmacol       Date:  1993-05

8.  Effects of adenyl nucleotides and carbachol on cooperative interactions among G proteins.

Authors:  P Chidiac; J W Wells
Journal:  Biochemistry       Date:  1992-11-10       Impact factor: 3.162

9.  Guanine nucleotide-sensitive interaction of a radiolabeled agonist with a phospholipase C-linked P2y-purinergic receptor.

Authors:  C L Cooper; A J Morris; T K Harden
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

10.  Cloning and functional expression of a brain G-protein-coupled ATP receptor.

Authors:  T E Webb; J Simon; B J Krishek; A N Bateson; T G Smart; B F King; G Burnstock; E A Barnard
Journal:  FEBS Lett       Date:  1993-06-14       Impact factor: 4.124

View more
  5 in total

Review 1.  Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms.

Authors:  E A Barnard; J Simon; T E Webb
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 2.  New insights on P2X purinoceptors.

Authors:  P P Humphrey; G Buell; I Kennedy; B S Khakh; A D Michel; A Surprenant; D J Trezise
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

3.  The binding characteristics of a human bladder recombinant P2X purinoceptor, labelled with [3H]-alpha beta meATP, [35S]-ATP gamma S or [33P]-ATP.

Authors:  A D Michel; K Lundström; G N Buell; A Surprenant; S Valera; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  A comparison of the binding characteristics of recombinant P2X1 and P2X2 purinoceptors.

Authors:  A D Michel; K Lundström; G N Buell; A Surprenant; S Valera; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes.

Authors:  A D Michel; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.